Clinuvel Pharmaceuticals Ltd has released a press release.
CLINUVEL update on Level II ADR upgrade, Nasdaq uplist
Earlier from Clinuvel Pharmaceuticals
- FDA relaxes SCENESSE postmarketing requirement
- CLINUVEL receives final EMA scientific advice for pivotal Phase III vitiligo study

